Akhilesh Kaushal1, Hongmei Zhang2, Wilfried J J Karmaus1, Todd M Everson3, Carmen J Marsit3, Margaret R Karagas4,5, Shih-Fen Tsai6, Hui-Ju Wen6, Shu-Li Wang6,7,8,9. 1. Division of Epidemiology, Biostatistics, and Environmental Health, University of Memphis, Memphis, TN, 38152, USA. 2. Division of Epidemiology, Biostatistics, and Environmental Health, University of Memphis, Memphis, TN, 38152, USA. hzhang6@memphis.edu. 3. Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA. 4. Department of Epidemiology, Geisel School of Medicine at Dartmouth College, Hanover, NH, USA. 5. Children's Environmental Health & Disease Prevention Research Center at Dartmouth, Hanover, NH, USA. 6. National Institute of Environmental Health Sciences, National Health Research Institutes, Miaoli, Taiwan. 7. School of Public Health, National Defense Medical Center, Taipei, Taiwan. 8. Department of Public Health, China Medical University, Taichung, Taiwan. 9. Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Abstract
BACKGROUND: In utero arsenic exposure may alter fetal developmental programming by altering DNA methylation, which may result in a higher risk of disease in later life. We evaluated the association between in utero arsenic exposure and DNA methylation (DNAm) in cord blood and its influence in later life. METHODS: Genome-wide DNA methylation in cord blood from 64 subjects in the Taiwanese maternal infant and birth cohort was analyzed. Robust regressions were applied to assess the association of DNA methylation with in utero arsenic exposure. Multiple testing was adjusted by controlling false discovery rate (FDR) of 0.05. The DAVID bioinformatics tool was implemented for functional annotation analyses on the detected CpGs. The identified CpGs were further tested in an independent cohort. For the CpGs replicated in the independent cohort, linear mixed models were applied to assess the association of DNA methylation with low-density lipoprotein (LDL) at different ages (2, 5, 8, 11 and 14 years). RESULTS: In total, 579 out of 385,183 CpGs were identified after adjusting for multiple testing (FDR = 0.05), of which ~60% were positively associated with arsenic exposure. Functional annotation analysis on these CpGs detected 17 KEGG pathways (FDR = 0.05) including pathways for cardiovascular diseases (CVD) and diabetes mellitus. In the independent cohort, about 46% (252 out of 553 CpGs) of the identified CpGs showed associations consistent with those in the study cohort. In total, 11 CpGs replicated in the independent cohort were in the pathways related to CVD and diabetes mellitus. Via longitudinal analyses, we found at 5 out of the 11 CpGs methylation was associated with LDL over time and interactions between DNA methylation and time were observed at 4 of the 5 CpGs, cg25189764 (coeff = 0.157, p-value = 0.047), cg04986899 (coeff. For interaction [coeff.int] = 0.030, p-value = 0.024), cg04903360 (coeff.int = 0.026, p-value = 0.032), cg08198265 (coeff.int = -0.063, p-value = 0.0021), cg10473311 (coeff.int = -0.021, p-value = 0.027). CONCLUSION: In utero arsenic exposure was associated with cord blood DNA methylation at various CpGs. The identified CpGs may help determine pathological epigenetic mechanisms linked to in utero arsenic exposure. Five CpGs (cg25189764, cg04986899, cg04903360, cg08198265 and cg10473311) may serve as epigenetic markers for changes in LDL later in life.
BACKGROUND: In utero arsenic exposure may alter fetal developmental programming by altering DNA methylation, which may result in a higher risk of disease in later life. We evaluated the association between in utero arsenic exposure and DNA methylation (DNAm) in cord blood and its influence in later life. METHODS: Genome-wide DNA methylation in cord blood from 64 subjects in the Taiwanese maternal infant and birth cohort was analyzed. Robust regressions were applied to assess the association of DNA methylation with in utero arsenic exposure. Multiple testing was adjusted by controlling false discovery rate (FDR) of 0.05. The DAVID bioinformatics tool was implemented for functional annotation analyses on the detected CpGs. The identified CpGs were further tested in an independent cohort. For the CpGs replicated in the independent cohort, linear mixed models were applied to assess the association of DNA methylation with low-density lipoprotein (LDL) at different ages (2, 5, 8, 11 and 14 years). RESULTS: In total, 579 out of 385,183 CpGs were identified after adjusting for multiple testing (FDR = 0.05), of which ~60% were positively associated with arsenic exposure. Functional annotation analysis on these CpGs detected 17 KEGG pathways (FDR = 0.05) including pathways for cardiovascular diseases (CVD) and diabetes mellitus. In the independent cohort, about 46% (252 out of 553 CpGs) of the identified CpGs showed associations consistent with those in the study cohort. In total, 11 CpGs replicated in the independent cohort were in the pathways related to CVD and diabetes mellitus. Via longitudinal analyses, we found at 5 out of the 11 CpGs methylation was associated with LDL over time and interactions between DNA methylation and time were observed at 4 of the 5 CpGs, cg25189764 (coeff = 0.157, p-value = 0.047), cg04986899 (coeff. For interaction [coeff.int] = 0.030, p-value = 0.024), cg04903360 (coeff.int = 0.026, p-value = 0.032), cg08198265 (coeff.int = -0.063, p-value = 0.0021), cg10473311 (coeff.int = -0.021, p-value = 0.027). CONCLUSION: In utero arsenic exposure was associated with cord blood DNA methylation at various CpGs. The identified CpGs may help determine pathological epigenetic mechanisms linked to in utero arsenic exposure. Five CpGs (cg25189764, cg04986899, cg04903360, cg08198265 and cg10473311) may serve as epigenetic markers for changes in LDL later in life.
Entities:
Keywords:
Arsenic; CpG; DAVID; DNA methylation; Genome-wide; KEGG pathway; Ldl
Authors: Yan Yuan; Guillermo Marshall; Catterina Ferreccio; Craig Steinmaus; Steve Selvin; Jane Liaw; Michael N Bates; Allan H Smith Journal: Am J Epidemiol Date: 2007-09-17 Impact factor: 4.897
Authors: Y Kajimoto; J Miyagawa; K Ishihara; Y Okuyama; Y Fujitani; M Itoh; H Yoshida; T Kaisho; T Matsuoka; H Watada; T Hanafusa; Y Yamasaki; T Kamada; Y Matsuzawa; T Hirano Journal: Biochem Biophys Res Commun Date: 1996-02-27 Impact factor: 3.575
Authors: R S Schmidli; P G Colman; L Cui; W P Yu; K Kewming; C Jankulovski; L C Harrison; C J Pallen; H J DeAizpurua Journal: Autoimmunity Date: 1998 Impact factor: 2.815
Authors: Abigail Fraser; Corrie Macdonald-Wallis; Kate Tilling; Andy Boyd; Jean Golding; George Davey Smith; John Henderson; John Macleod; Lynn Molloy; Andy Ness; Susan Ring; Scott M Nelson; Debbie A Lawlor Journal: Int J Epidemiol Date: 2012-04-16 Impact factor: 7.196
Authors: Andy Boyd; Jean Golding; John Macleod; Debbie A Lawlor; Abigail Fraser; John Henderson; Lynn Molloy; Andy Ness; Susan Ring; George Davey Smith Journal: Int J Epidemiol Date: 2012-04-16 Impact factor: 7.196
Authors: Devin C Koestler; Michele Avissar-Whiting; E Andres Houseman; Margaret R Karagas; Carmen J Marsit Journal: Environ Health Perspect Date: 2013-06-11 Impact factor: 9.031
Authors: John Dou; Rebecca J Schmidt; Kelly S Benke; Craig Newschaffer; Irva Hertz-Picciotto; Lisa A Croen; Ana-Maria Iosif; Janine M LaSalle; M Daniele Fallin; Kelly M Bakulski Journal: Epigenetics Date: 2018-02-16 Impact factor: 4.528
Authors: Naomi E Tinkelman; Miranda Jones Spratlen; Arce Domingo-Relloso; Maria Tellez-Plaza; Maria Grau-Perez; Kevin A Francesconi; Walter Goessler; Barbara V Howard; Jean MacCluer; Kari E North; Jason G Umans; Pam Factor-Litvak; Shelley A Cole; Ana Navas-Acien Journal: Environ Int Date: 2020-02-18 Impact factor: 9.621
Authors: Anne K Bozack; Andres Cardenas; Quazi Quamruzzaman; Mahmuder Rahman; Golam Mostofa; David C Christiani; Molly L Kile Journal: Epigenetics Date: 2018-10-11 Impact factor: 4.528
Authors: Ana Navas-Acien; Miranda J Spratlen; Ahlam Abuawad; Nancy J LoIacono; Anne K Bozack; Mary V Gamble Journal: Curr Diab Rep Date: 2019-11-22 Impact factor: 4.810